Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-611
- Development stage
- Preclinical
- Lead developer
- Amyloid Solution
- Modality
- Small Molecules
01
Overview
AS-611 is a small molecule therapeutic candidate being developed by Amyloid Solution for the treatment of Alzheimer's disease. It is part of the company's AMYLOID program and is designed to target the Tau protein, a key pathological driver in neurodegenerative diseases characterized by the formation of neurofibrillary tangles. Currently in the discovery stage, AS-611 aims to address the underlying proteinopathy associated with cognitive decline in Alzheimer's patients. The specific mechanism of action regarding how it interacts with Tau (e.g., inhibition of aggregation or degradation) has not been publicly disclosed.
02
Targets
Amyloid-beta aggregate (N-terminal epitope)Tau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on AS-611.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS-611.